Journal for Research in Applied Sciences and Biotechnology

www.jrasb.com

ISSN: 2583-4053

Volume-3 Issue-3 || June 2024 || PP. 170-180

https://doi.org/10.55544/jrasb.3.3.27

A Comprehensive Review on Hepatic Encephalopathy: Pathophysiology, Symptoms, Epidemiology, Classification, Diagnosis and Treatment

Sandip Tejpal[1], Saajan Kumar Sharma[1], Astha Sharma[1] and Sachit Sharma[1*]

[1]Department of Pharmaceutical Sciences, Guru Nanak Dev University, Grand Trunk Road, Off NH 1, Amritsar-143005, Punjab, INDIA.

[*]Corresponding Author: sachitsharma17012001@gmail.com

www.jrasb.com || Vol. 3 No. 3 (2024): July Issue

Received: 20-06-2024	**Revised:** 30-06-2024	**Accepted:** 01-07-2024

ABSTRACT

The condition known as hepatic encephalopathy (HE) is a state of impaired brain function that can be reversed and is experienced by patients who are suffering from severe liver diseases. Neurotoxins, decreased neurotransmission as a result of metabolic anomalies in liver failure, changes in brain energy metabolism, systemic inflammatory response, and alterations of the blood brain barrier are the primary hypotheses that are still being explored in relation to the precise pathophysiology of hepatic encephalopathy (HE). There is a wide spectrum of severity regarding the neurological and mental symptoms that can be brought on by HE. For the purpose of diagnosing limited HE, abnormal psychometric tests are utilised. Alterations in personality, altered states of consciousness, gradual spatial and temporal disorientation, lethargy, stupor, and coma are some of the characteristics of HE that are clinically noticeable. For the purpose of diagnosis, specific testing is not required outside of clinical studies. HE is classified according to the underlying disease, the severity of symptoms, the length of time it has been present, and whether or not there are triggers that cause it to occur. Hepatic encephalopathy refers to a collection of neuropsychiatric illnesses that can be treated and are characterised by the presence of symptoms in individuals who have liver disease or who have undergone portosystemic shunting. Entephalopathy, a disabling result of cirrhosis, affects thirty-five percent to forty-five percent of cirrhotic patients. Before recently, the treatment choices for HE that were available in hospitals were depending on anecdotal evidence, the availability of medication, and the norms of the relevant institutions. An increasing number of randomised controlled trials (RCTs) are providing further confirmation of the central significance of the basic HE therapy techniques (lactulose, branched-chain amino acids, and rifaximin), as well as the rising body of evidence showing the large beneficial advantages associated with these strategies. The liver transplantation and embolisation of large PSSs are two treatments that have proven to be effective for a select group of patients who have been carefully selected. Not only does it have a significant influence on the day-to-day lives of patients and carers, but it is also associated with increased rates of sickness and death and consumes a significant amount of resources in the healthcare system. In this article, we examine the history of hepatic encephalopathy, as well as the current understanding of the condition and the potential treatments for it.

Keywords- Hepatic encephalopathy, Pathophysiology, Diagnosis, Treatment.

I. INTRODUCTION

It is possible for patients who are experiencing extensive liver failure to encounter a condition known as hepatic encephalopathy (HE) or portosystemic encephalopathy (PSE), which is a state of impaired brain function that can be reversed. It is important to note that a single clinical item does not define HE[1]. Depending on the circumstances, it may be an indicator of reversible metabolic encephalopathy, brain atrophy, or brain edoema[2]. We are yet unsure of the factors that lead to brain dysfunction in patients with liver failure. There is a direct connection between these variables and liver failure, which can be demonstrated by examples such as decreased ammonia metabolism[3]. Unless the underlying liver problem is appropriately addressed, there

Journal for Research in Applied Sciences and Biotechnology

www.jrasb.com

ISSN: 2583-4053

Volume-3 Issue-3 || June 2024 || PP. 170-180

https://doi.org/10.55544/jrasb.3.3.27

is a significant chance of recurrence and poor survival associated with hepatic encephalopathy without proper treatment. In spite of this, mild HE is linked to a decrease in health-related quality of life as well as an increased probability of experiencing more severe bouts of the condition[4].

Patients with cirrhosis frequently suffer from a complicated neurological condition known as type-C hepatic encephalopathy (HE), which is characterised by a wide range of neurological and mental symptoms that are not unique to specific conditions. Severe hepatocellular failure or the existence of huge portal-systemic shunts are the two factors that determine the occurrence of this condition[5]. This sickness can range from subclinical to completely altered awareness, with the mildest type being known as minimal hepatic encephalopathy (MHE) and the most severe form being known as overt hepatic encephalopathy (OHE). During the course of the natural history of their disease, OHE develops in 30-40% of individuals who have cirrhosis of the liver, however it is difficult to determine the exact prevalence of the condition[6]. Patients who have undergone a transjugular intrahepatic portosystemic shunt (TIPS), patients who have a history of shunting, whether it be spontaneous or surgical, and patients who have a higher risk of having hepatic embolism (HE) may have significantly higher prevalence rates[7].

In order to diagnose MHE, which "apparently" lacks any clinical proof, the only methods that may be utilised are psychometric evaluations, electrophysiological tests, and other functional brain evaluations[8]. Despite the fact that the precise prevalence of MHE is still up for debate, estimates range anywhere from twenty percent to eighty percent of patients. When it comes to therapeutic treatment, however, MHE is significant because of its correlations with patients' falls, driving fitness, work capacity, sarcopenia, prognosis, and the degradation of patients' and carers' lives as a result of changes in socioeconomic status and quality of life[9].

One of the new words that has been produced to represent a condition that is evident but not overt is "covert," which was developed as a result of the merger of MHE and Grade I HE. Twenty-five percent to five percent of people who have been diagnosed with cirrhosis will develop obstructive hepatic encephalopathy (OHE) within five years of receiving the diagnosis[10,11].

Both MHE and CHE are substantial risk factors for this condition. Depending on how they develop over time, there are three distinct types of HE: episodic HE, which is caused by external stimuli; recurrent HE, which occurs more than once every six months; and persistent HE, which is marked by ongoing neurological alterations interspersed with OHE relapses. Each of these types of HE is characterised by a distinctive progression of symptoms over time[12].

II. PATHOPHYSIOLOGY

Ammonia (NH3), inflammatory cytokines, manganese accumulation in the basal ganglia, and benzodiazepine-like substances, such as gamma-amino butyric acid (GABA), are some of the factors that contribute to the pathophysiology of hepatic encephalopathy (HE)[13]. Recent study has also suggested that aromatic amino acids and microbiota may play a role in the phenomenon. Despite the fact that the pathogenesis of HE is a multi-faceted process (Figure 1) that involves numerous components leading to functional impairment of neuronal cells, NH3 has been the primary pathophysiologic mechanism of HE up until this point. None of these components are entirely understood[14]. The production of NH_3, a nitrogenous toxin that is mostly received from the gut, is the result of the breakdown of urea from human dietary proteins using bacteria. As soon as the liver has finished metabolising NH_3, it is eliminated from the body by the kidneys and, to a lesser extent, by the muscles[15]. Portal hypertension is a condition that leads to the redirection of NH3-rich portal blood to the systemic circulation without any detoxification taking place. On the other hand, liver dysfunction makes it difficult for the liver to break down NH_3 in cirrhotic patients[16]. In the brain, astrocytes are responsible for the metabolism of NH_3 through the use of glutamine synthetase, which converts NH3 and glutamate into glutamine from the former.



Fig 1: Multiorgan ammonia pathways with specific ammonia-lowering medications used in cirrhosis.

Cirrhosis is linked to decreased urea cycle capability and glutamine synthetase activity in the liver, both of which contribute to astrocyte enlargement and hepatic encephalopathy. Additionally, circulating ammonia (NH_3) concentrations are raised due to the involvement of multiple organs in the generation of NH_3. Moreover, the alternative approach is displayed at the very top of the page. Glutamine synthetase (GS) is responsible for the enzymatic transformation of glutamate (GLU) into glutamine (GLN) in this particular route. Glycerol phenylbutyrate (GPB) and ornithine phenylacetate (OP) are two ammonia-lowering medicines

ISSN: 2583-4053

Volume-3 Issue-3 || June 2024 || PP. 170-180

https://doi.org/10.55544/jrasb.3.3.27

that, when combined with phenylacetate (PAA) and glycerol, result in the production of phenylacetylglutamine (PAGN) that is excreted. By demonstrating its ability to bind to NH_3 in the digestive tract, the carbon microsphere adsorbent known as AST-120 has the potential to lower the levels of ammonia in the blood. In addition to its cathartic properties, polyethylene glycol (PEG) has the ability to hasten the elimination of bacteria in the digestive tract that are responsible for the production of ammonia through the stool. Approximately one quarter of the byproducts of the urea cycle are taken in by the colon, while the kidneys are responsible for excreting three quarters of them. Colon bacteria that produce urease are responsible for the production of ammonia, which is then transported to the portal circulation. It has been demonstrated that skeletal muscle also plays a role in the regulation of NH_3. In the illustration, neither the glutaminase nor the glutaminase levels of each organ are shown. These levels are important for maintaining NH_3 homeostasis.

The accumulation of glutamine in astrocytes, which results in an osmotic gradient, which in turn results in astrocyte enlargement and the formation of reactive oxygen species, is one of the factors that contribute to the dysfunction of the brain that is found in healthy individuals with hypertension[17]. One of the consequences of dysbiosis and increased gut permeability in cirrhosis is an increase in the production of a variety of inflammatory cytokines. This, in turn, leads to an increase in the permeability of the blood-brain barrier and cerebral edoema. Activation and synthesis of neurosteroids are two additional factors that contribute to the development of HE. These neurosteroids are produced as a result of ammonia binding to GABA receptors on astrocytes[18]. As a result of its neurotoxic properties, NH_3 causes neurons to depolarize, raises the resting membrane potential, and deactivates the chloride extrusion pumps that are found in neurons. Because of this, axonal conduction and excitatory postsynaptic potentials are inhibited, which in turn suppresses the production of inhibitory postsynaptic potentials[19]. It is possible that by the time the disease progresses, total brain NH_3 in HE will not have increased to a level that causes changes in postsynaptic potentials; but, it will undoubtedly contribute to asterixis. Glutaminase haplotypes are linked to both overt hyperemia and elevated mitochondrial NH_3, which causes reactive nitrogen and oxygen species to worsen brain edoema. Both of these conditions are associated with brain edoema. When it comes to HE, glutamate is the most important amino acid involved[20]

As a result of the fact that overt HE is associated with elevated NH_3 levels, new study suggests that various interactions with the microbiota in the gut may play a significant role in the development of HE. One of the potential causes of dysbiosis in cirrhotic patients is the metabolism of bile acids[21]. Both the destabilisation of bacterial membranes and the increase in intestinal permeability are responsible for the antibacterial impact. This occurs when commensal bacteria obtain energy from main bile acids, which then convert to secondary bile acids (for example, cholic acid → deoxycholic acid). The microbiome enters a state of dysbiosis as a result of increased inflammation and cholestasis brought on by decompensated cirrhosis[22]. This, in turn, leads to a decrease in the synthesis of bile acids in the liver, which in turn leads to an overgrowth of dangerous bacteria due to a decrease in the amount of bile acids produced by the intestinal tract. A decrease in the ratio of primary to secondary bile acids is one of the defining characteristics of cirrhosis. This decrease in ratio leads to alterations in the microbiota of the gut, which in turn leads to a reduction in commensal bacteria. Individuals who have cirrhosis experience changes in other dangerous bacteria, such as an increase in Enterobacteriaceae and a simultaneous drop in the commensal bacterium Lachnospiraceae, as well as an increase in the ratio of Bacteroides to Firmicutes. Under conditions where there were no germs present, there was no evidence of brain inflammation or hyperammonemia, which is evidence of the significant role that gut microbiota plays in the pathogenesis of HE. In this investigation, a mouse model of cirrhosis was used, and the results were compared to those obtained from cirrhotic mice that were reared normally[23].

There is also the possibility that proton pump inhibitors (PPIs) make the dysbiosis that is seen in cirrhotic patients more worse. The drop in stomach acidity makes it easier for intestinal bacteria to overgrow, which in turn raises the risk of germs leaving the gut and moving to other parts of the body. This finding has caused some people to express their concerns on the possible connection between PPI and the development of HE[24]. Dam and colleagues reviewed data from clinical studies that evaluated the efficacy of satavaptan in patients with ascites and cirrhosis in order to identify whether or not proton pump inhibitors (PPIs) increased the incidence of first-time hepatic embolism (HE). When compared to individuals who did not take proton pump inhibitors at the beginning of the study, those who did had a cumulative risk of developing HE over the course of a year that was 31% higher than those who did not take them. 38% of patients with cirrhosis and hepatic endothelial (HE) had taken proton pump inhibitors (PPIs) prior to the development of hepatic endothelial inflammation (n = 445), as indicated by a case-control study conducted in Taiwan[25].

III. SYMPTOMS AND SIGNS

Hepatic encephalopathy (HE) is a condition that can result in a wide range of neurological and behavioural symptoms that are systemic in nature. Confusion and a diminished capacity for mental clarity are also signs that the brain is malfunctioning. At an early stage, there are subtle modifications in not only thought but also behaviour and attitude. There is a possibility that the

ISSN: 2583-4053

Volume-3 Issue-3 || June 2024 || PP. 170-180

https://doi.org/10.55544/jrasb.3.3.27

individual's perspective will shift, and that their capacity to make rational choices will be hindered. Interruptions to regular sleep patterns are possible. A person might have feelings of rage, despair, or anxiety. Many people have short attention spans. During any stage of encephalopathy in the patient, it is possible to notice a musty and pleasant fragrance coming from their breath. Mild HE can present itself in a number of different ways, such as having sweet or musty breath, experiencing changes in personality or analytical abilities, being unable to concentrate, having difficulty writing or losing other fine motor skills, being disoriented, forgetting things, and having bad judgement. Concern, tiredness or sleepiness, uneasiness, convulsions, dramatic changes in personality, fatigue, sluggish movements, shaky hands, and speech that is incomprehensible are some of the symptoms that may indicate you are suffering from severe HE[26].

The progression of the illness causes patients to have a more difficult time keeping their hands still when they are reaching out, which results in a more awkward flailing motion known as asterixis. In response to unexpected stimuli such as bright lights, rapid movements, or loud noises, certain individuals have the tendency to jerk their muscles without even being aware of it. There is a jerky that goes by the name of Myoclonus. Sluggishness, disorientation, and slurred speech are additional symptoms that patients frequently report experiencing. A feeling of confusion is a natural occurrence. Irritability and rage are symptoms that are infrequently seen by patients who have encephalopathy. They are at risk of passing out and entering a coma at some point due to the fact that their liver function continues to decline. Coma frequently results in death, even when therapy is administered[27].

IV. EPIDEMIOLOGY

Within the range of 5 years, around 44 percent of individuals who have cirrhosis are at risk of developing hepatic encephalopathy, as indicated by a population-based study[28]. In another study, which examined more than 9000 individuals with cirrhosis, it was shown that 33 percent of those patients had decompensated cirrhosis, and 51 percent of those patients had hepatic encephalopathy because of their condition. Due to the fact that chronic liver disease typically causes a gradual and modest onset, many individuals who suffer from the condition wait until they have symptoms before seeking treatment[29]. An estimated 202,000 cases of hepatic encephalopathy were documented in the United States in 2018, as shown by a study that made use of the commercial medical claims database. It should be emphasised that mild hepatic encephalopathy, which affects as many as 80 percent of cirrhotic patients and is identifiable by minor symptoms that require specialised testing, may have been neglected in this study[30].

V. CLASSIFICATION OF HEPATIC ENCEPHALOPATHY

There is a wide range of symptoms that may be associated with the clinical presentation of HE. These symptoms may include, but are not limited to, cognitive, personality, and mental abnormalities; altered states of consciousness; and poor neuromuscular function (including asterixis and hyperreflexia). The multitude of symptoms associated with HE may shift not only between individuals but also over the course of time within an individual[31]. The concept of minimal HE (mHE) was also conceived as a result of the crucial discovery that cirrhotic persons who appear to be clinically "normal" may in fact have abnormalities on electroencephalography and neuropsychometric tests[32]. A multiaxial definition of hepatohepatitis (HE) was developed by the World Organisation of Gastroenterology in 1998 in order to solve the difficulty of precisely describing and classifying the severity of the condition. HE was classified according to four factors in this definition: (1) the aetiology (Type A, which refers to acute liver failure; Type B, which refers to portosystemic bypass without intrinsic liver disease; and Type C, which refers to cirrhosis); (2) the severity (minimal or West Haven Grade 1-4 [Table 1]); (3) the time course (episodic, recurrent, persistent); and (4) the precipitated versus spontaneous nature of the condition[33]. This category had minor modifications in 2014 as a result of the EASL-AASLD consensus, although it nevertheless maintained its fundamental characteristics.

The subjective and arbitrary West Haven Criteria, which categorises HE into four phases based only on clinical criteria, is frequently utilised by medical professionals in their day-to-day practice[34]. This is in contrast to the practice of taking into account all manifestations that occur during a certain stage. The fundamental disadvantage of this method is that it has a high degree of inter- and intra-observer variability when it comes to reliably identifying grade 1 HE patients, as opposed to individuals who have no HE or mild HE. This is despite the fact that it is effective for identifying patients who are at the extremes of the scale[35]. The utilisation of the Hepatic Encephalopathy Scoring Algorithm (HESA), which integrates clinical and neuropsychological evaluation, has been shown to result in an improvement in the grading sensitivity of clinical studies. The Clinical Hepatic Encephalopathy Staging Scale (CHESS) is a more contemporary method that grades the severity of hepatic encephalopathy (HE) on a linear scale ranging from 1 to 9. However, it is not widely used. It is possible to differentiate Grade II HE from Grade I HE with greater ease by employing disorientation and asterixis as their respective markers. Consequently, the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) has put out a proposition to label HE Grade ≥II as Overt Hepatic Encephalopathy (OHE), whilst Grade 1 and mHE have the potential to be

ISSN: 2583-4053
Volume-3 Issue-3 || June 2024 || PP. 170-180
https://doi.org/10.55544/jrasb.3.3.27

categorised as Covert Hepatic Encephalopathy (CHE)[36]. OHE and CHE can be considered as genuine positions along the continuum of neurocognitive impairment in cirrhosis, which is a paradigm change away from categorical thinking about the spectrum of neurocognitive impairment in cirrhosis-related conditions. Given that it is simply an umbrella concept, the term "CHE" has a restricted range of application[37]. An examination of 132 cirrhotics revealed that the syndrome is heterogeneous and necessitates a battery of clinical and neuropsychometric testing in order to arrive at a diagnosis of chronic hepatitis infection (CHE). The classification of Grade 1 HE and mHE as CHE may be deceptive due to the fact that, as demonstrated in a recent prospective study conducted by Thomsen et al., individuals who have mHE and Grade 1 HE are distinct from one another in terms of their clinical, pathophysiological, and genetic characteristics[38]. The exact and speedy classification of the severity of HE not only provides essential functional information on the patient's current clinical status, but it also defines objective standards for research and trials connected to HE[39,40]. Important prediction information is also provided by this classification[41]. As a result of the fact that the absence of HE does not necessarily signify the absence of neuropsychometric problems, the current challenge consists of specifying what constitutes "normal" and then determining the most effective methods for properly and consistently detecting early HE[42]. In the event that any abnormality is to be regarded as HE, Montagnese et al. claim that it is advantageous to take into consideration a person's historical neuropsychometric performance as well as any co-morbidities that they experienced[43,44].

Table 1: West Haven criteria for grading severity of HE

Grade	Clinical features
I	Trivial lack of awareness Euphoria or anxiety Shortened attention span Impairment of addition or substraction
II	Lethargy or apathy Personality change Disorientation for time Inappropiate behaviour
III	Somnolence to semi-stupor Confusion Gross disorientation
IV	Coma

VI. DIAGNOSIS

Based mostly on clinical evidence, hepatic encephalopathy is a diagnosis that is considered to be an excluding diagnosis. Before determining that HE is the cause of the neurocognitive impairment, it is necessary to rule out any other potential reasons of altered mentation[45]. In the event that a patient with cirrhosis is experiencing difficulties with their mental capacity, it can be beneficial to conduct one of the many cognitive dysfunction tests that are currently accessible. While the West Haven Criteria is generally recognised and utilised as the gold standard in clinical diagnostics, it is not without its limitations due to the fact that it is subjective[46]. Disorientation and asterixis are two clinical indications that can be relied upon to indicate direct hypertension. The diagnosis of covert HE is more difficult than the diagnosis of overt HE, which is easy to identify[47]. It is possible to categorise these evaluations into two major categories: neuropsychological and psychometric evaluations. The ISHEN also recommends conducting at least two different tests due to the fact that HE can influence a wide variety of aspects of cognition. Evaluations for subtle and hidden hepatic encephalopathy can be used to identify patients who are at a high risk for developing the condition. Those individuals who are at risk of developing evident HE can be identified by this method. If these individuals also have preclinical mentation impairment, it indicates that their quality of life may be deteriorating[48]. Even patients with mild or subtle HE may nonetheless face certain challenges in their professional lives over the course of their careers. Education in this field can be beneficial to patients and the people who care about them, provided that we are able to locate examples such as this one. Testing should only be performed in situations when there are no other medical conditions or circumstances that could impair mentation, such as psychiatric diseases, sedative medicines, or alcohol intake. This is because the expense of testing is extremely high. If everything appears to be in order, it is recommended that you retake the test after a period of six months[49].

VII. NEUROPSYCHOLOGICAL AND PSYCHOMETRIC TEST

- In the Portosystemic encephalopathy (PSE) syndrome examination, which is conducted using a paper-and-pencil format, cognitive and psychomotor processing speed, as well as visual-motor coordination, are all evaluated.
- This computerised evaluation evaluates how long it takes for a person to react physically in response to an aural input; as a result, it does require synchronisation between the two processes. The Continuous Reaction Time (CRT) test is an example of this type of evaluation.
- In the Critical Flicker Frequency (CFF) test, the patient is given a fused light and instructed to take note of the frequency of its flickering. This test is performed when the patient's neurocognition begins to degrade.
- This computerised assessment of psychomotor speed and cognitive flexibility is known as the Stroop test,

ISSN: 2583-4053
Volume-3 Issue-3 || June 2024 || PP. 170-180
https://doi.org/10.55544/jrasb.3.3.27

and it may be accessed through an application that is available for smartphones.

- An example of such a computerised test is the Inhibitory Control Test (ICT), which evaluates both response inhibition and working memory simultaneously.
- The SCAN Test is a computerised examination that tests the patient's precision and speed by having them do progressively more difficult digit identification activities.
- The electroencephalogram, sometimes known as an EEG, is a technique that evaluates the activity of the brain without requiring the patient to do any actions. However, hyponatremia and sedative medications, both of which are metabolic causes of encephalopathy, can also have an effect on EEG data and make interpretation more challenging.

Laboratory tests

The levels of ammonia do not have a correlation with the severity or stage of HE, and because of this, they are not considered to be diagnostic markers. A normal level, on the other hand, might suggest that there is an additional issue that needs to be addressed. Additional testing in the laboratory would be carried out in order to eliminate the possibility of any other potential causes.

Neuro-imaging

As a result of the fact that patients with HE frequently exhibit aberrant mentation, a CT brain scan is routinely obtained in order to validate the suspicion that an intracranial disease is present.

VIII. TREATMENT / MANAGEMENT

Reducing ammonia levels and providing supportive care are typically the two components that make up the treatment for hepatic encephalopathy. The provision of enough nourishment, the prevention of electrolyte imbalances and dehydration, and the establishment of a secure environment that is devoid of any hazards that could lead to accidents or falls are all essential components of supportive care. Antibiotics such as rifaximin and disaccharides such as lactulose and lactitol are the primary components of treatment for lowering ammonia levels[50].

Nutritional support: Patients who are diagnosed with hepatic encephalopathy should not restrict their consumption of protein, as this is not suggested. Through the use of nutritional supplements, they should be given a calorie intake that is more appropriate, which should be somewhere between 35 and 40 kcal/kg/day[51]. According to this diet plan, the amount of protein that one consumes on a daily basis should remain between 1.2 and 1.5 grammes per kilogramme. Maintaining a focus on eating multiple small meals that are spaced out throughout the day is necessary in order to avoid fasting, which can lead to an increase in the production of ammonias. Patients who experience a worsening of their symptoms when they consume protein might want to consider vegetarian protein as an alternative. Additionally, individuals who have difficulty digesting protein may find relief by including branched-chain amino acids (BCAA) in a diet that is low in protein[52]. The use of this approach is extremely beneficial for patients who have experienced hepatic encephalopathy as a result of surgical procedures such as TIPS or surgical portosystemic shunts.

Hydration and electrolyte correction: The provision of supportive care also includes ensuring that the patient is adequately hydrated and correcting any electrolyte imbalances that may exist. Among these measures is ensuring that the patient consumes a enough amount of fluids by oral consumption and, if necessary, administering intravenous hydration to prevent them from getting dehydrated. In the case that there are abnormalities in the electrolyte levels, it is essential to promptly restore the electrolytes that are considered to be necessary[53].

Safe environment: The establishment of a safe environment for individuals who are displaying visible symptoms is of the utmost importance[54]. Symptoms that these individuals may exhibit include agitation as well as the potential for harm to both themselves and their carers. In the process of addressing the patient's restlessness, it is important to keep in mind that benzodiazepines and other sedatives have the potential to exacerbate encephalopathy and slow down the healing process[55]. Consequently, the administration of these medications ought to be carried out with extreme caution, and until the patient's level of agitation decreases, it might be necessary to employ temporary restraints.

Addressing and treating the precipitating factors: It is imperative that the underlying causes of hepatic encephalopathy be recognised and addressed as quickly as possible. There are a number of circumstances that have the potential to operate as triggers[56]. Some of these diseases include infections (such urinary tract infections or spontaneous bacterial peritonitis), metabolic and electrolyte problems (like hypokalemia or hypoglycemia), hypovolemia, and the use of benzodiazepines or other sedatives. The rapid implementation of solutions to these problems is required in order to ensure that they are effectively managed[57].

Lowering ammonia: Even though elevated ammonia levels are frequently observed in cases of hepatic encephalopathy, this does not always mean that they are present in every single occurrence[58]. After a diagnosis of hepatic encephalopathy has been made, it is critical to take measures to lower ammonia levels, regardless of whether or not the levels are elevated. When blood ammonia levels are high but there are no clinical symptoms of hepatic encephalopathy present, medication that lowers ammonia levels is not required. This is equally true in the opposite direction. Rather than relying solely on ammonia levels, the choice to begin such treatment ought to be informed by clinical evaluation in conjunction with the presence of symptoms of hepatic encephalopathy[59]. One of the most frequently

ISSN: 2583-4053
Volume-3 Issue-3 || June 2024 || PP. 170-180
https://doi.org/10.55544/jrasb.3.3.27

prescribed medications for treatment is rifaximin, which is an antibiotic. Other disaccharides, such as lactulose and lactitol, are also effective.

Lactulose: The action of lactulose can be carried out in a variety of different ways. Intestinal bacteria are responsible for the breakdown of lactulose, which results in a fall in pH. Because of this, there is a decrease in the amount of ammonia (NH3) that is released into the circulation, and there is an increase in the amount of ammonium (NH4+) that is created during the conversion process. Additionally, by enhancing the diffusion of NH3 from the blood into NH4+ in the stomach, lactulose makes the process of converting NH3 into NH4+ easier by its presence. In addition to this, it acts as an osmotic agent, which induces distention and peristalsis, which in turn helps the colon produce more NH3. Lactulose is able to successfully reduce the levels of ammonia in the blood through multiple processes. Twenty to thirty grammes is the typical dosage, and it should be taken twice or three times per day in order to induce two or three soft stools in a single day. In the event that swallowing is not an option, you can alternatively administer it through an enema[60]. About seventy to eighty percent of people who have hepatic encephalopathy see an improvement after receiving treatment with lactulose. Despite the fact that lactitol is available in other countries, the United States of America does not have access to purchasing it.

Rifaximin: It is because of the poor absorption of rifaximin in the digestive system that there is an elevated concentration in the intestines because of this. The bacteria in the colon that are responsible for producing ammonia are thought to be eliminated by this method, which is the idea behind its ability to reduce ammonia production[61]. Through its ability to bind to DNA-dependent RNA polymerase, rifaximin is able to accomplish this by inhibiting the production of RNA by bacteria. Those patients who are unable to tolerate lactulose or lactitol, or who do not respond to either of these alternatives, might be candidates for this alternative. Oral administration of 550 milligrammes twice daily or oral administration of 400 milligrammes three times daily is the typical dosage of rifaximin.

Neomycin: Since the beginning of antibiotic research, neomycin has been the subject of investigation as a possible agent that can reduce the number of bacteria in the colon that produce ammonia. According to randomised clinical trials, the effectiveness of neomycin in the treatment of hepatic encephalopathy has been proven in a manner that is not consistent[62]. Other potential adverse effects of neomycin include nephrotoxicity and ototoxicity, both of which are potentially harmful. The use of neomycin is uncommon because of the risks associated with it and the fact that it is not very effective.

Ornithine-aspartate: This chemical, known as ornithine-aspartate, is an alternative treatment for hepatic encephalopathy. It works by boosting the metabolism of ammonia, which in turn increases the amount of ammonia that is used in the urea cycle to produce urea[63]. Having stated that, it is typically not something that can be obtained in clinical settings.

Chronic management: The identification and management of potential triggering reasons is of the utmost importance for individuals who are at risk of experiencing recurrent hepatic encephalopathy[64]. Disaccharides like lactulose or lactitol, when taken with rifaximin, can be an effective and continuing treatment option for patients who are unable to identify or appropriately control a factor that is causing their condition.

Liver transplantation: When a patient with cirrhosis develops a major-index consequence (such ascites, hepatic encephalopathy, or variceal haemorrhage), or when their Model of End-Stage Liver Disease (MELD) score is greater than 15, liver transplantation may be an option that is taken into consideration[65]. The findings imply that cognitive impairment brought on by hepatic encephalopathy can be reversed within five years of the transplant in patients who fit the requirements for the treatment and continue to undergo it. In light of this, it is important to note that cognitive performance and quality of life may experience significant improvements after a successful liver transplant.

IX. FUTURE PROSPECTS

Rifaximin has been incorporated into the treatment recommendations that are currently in place, which has resulted in a considerable change in the way that HE is managed over the course of the last ten years. The number of randomised controlled trials that document the use of lactulose, rifaximin, GPB, and other substances has increased, and the quality of the evidence available has also improved. It is necessary to conduct additional study into the pathogenesis of HE in order to create fresh methods to the treatment of the condition. The outcomes of a number of randomised clinical trials, such as STOP-HE and HALT-HE, are being anxiously anticipated by researchers.

When studying pathophysiology, it is essential to place a strong emphasis on gaining a grasp of the role that a number of different concepts play in the development of HE. It would be fascinating to study how nutritional therapy impacts this population for the reason that studies on the gut flora have showed hopeful effects. Both the Prometheus device and the Molecular Adsorbent Recirculating System are examples of liver support systems that have demonstrated some degree of potential despite their limitations. They work by removing toxins from the bloodstream that have accumulated as a consequence of liver failure. This is the method by which they exercise their influence. In randomised clinical studies, the effects of both devices on hepatic encephalopathy (HE) were investigated, and patients with liver failure indicated that they were well tolerated. The MARS system performed far better in terms of HE and

ISSN: 2583-4053

Volume-3 Issue-3 || June 2024 || PP. 170-180

https://doi.org/10.55544/jrasb.3.3.27

had a significantly faster response time as compared to conventional medical treatment, as demonstrated by the MARS study. The same thing was discovered during the Relief study, with the difference that the survival improvements were not demonstrated successfully. It is probable that these devices will only be viable as a stopgap measure until transplantation is possible for persons who have crippling HE. This is because the need for central venous access and the unpredictability of treatment timetables mean that these devices are necessary. There is a need for additional study to be conducted on the cost-effectiveness and concerns around sepsis for the reason.

X. CONCLUSION

Strong evidence suggests that hepatic encephalopathy (HE) is a factor in the morbidity that occurs in people who have cirrhosis and end-stage liver disease. Patients suffer a significant decline in their level of living as a result of the unpredictability of HE, which has a devastating impact on them. In order to prevent further irreparable damage to the brain parenchyma, the first thing that should be done is to strongly encourage the patient to quit drinking and to start taking lactulose solution as soon as possible in order to bring down the levels of alcohol in their blood. As a result of the researchers' investigation into the complexity of HE, they have discovered novel and potentially useful therapeutic alternatives. With regard to the majority of pharmaceutical approaches, there is still a great deal of debate over whether or not they are effective in treating HE. The majority of patients are able to be treated for this problem as a result of the strategies for HE treatment that have been successfully created through empirical research. Among these measures are the identification and treatment of the precipitating event, the provision of general support to patients who have episodic HE, and the reduction of blood flow through a massive portal-systemic shunt for patients who have recurrent or persistent HE. As a matter of fact, the core of HE therapy is still the pathophysiological assumption that the failing liver does not clear nitrogen compounds from the stomach and that these molecules are relevant to the alterations that are occurring in the central nervous system.

REFERENCES

[1] Kaplan, P. W., & Rossetti, A. O. (2011). EEG patterns and imaging correlations in encephalopathy: encephalopathy part II. *Journal of Clinical Neurophysiology*, *28*(3), 233-251.

[2] D'amico, G., Morabito, A., Pagliaro, L., Marubini, E., & Liver Study Group of "V. Cervello" Hospital. (1986). Survival and prognostic indicators in compensated and decompensated cirrhosis. *Digestive diseases and sciences*, *31*, 468-475.

[3] Ito, T., Ikeda, N., Watanabe, A., Sue, K., Kakio, T., Mimura, H., & Tsuji, T. (1992). Obliteration of portal systemic shunts as therapy for hepatic encephalopathy in patients with non-cirrhotic portal hypertension. *Gastroenterologia Japonica*, *27*, 759-764.

[4] Vilstrup, H., Amodio, P., Bajaj, J., Cordoba, J., Ferenci, P., Mullen, K. D., ... & Wong, P. (2014). Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. *Hepatology*, *60*(2), 715-735.

[5] Bai, M., Qi, X., Yang, Z., Yin, Z., Nie, Y., Yuan, S., ... & Fan, D. (2011). Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: a systematic review. *Journal of gastroenterology and hepatology*, *26*(6), 943-951.

[6] Riggio, O., Efrati, C., Catalano, C., Pediconi, F., Mecarelli, O., Accornero, N., ... & Merli, M. (2005). High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: a case-control study. *Hepatology*, *42*(5), 1158-1165.

[7] Simón-Talero, M., Roccarina, D., Martínez, J., Lampichler, K., Baiges, A., Low, G., ... & Botella, E. R. (2018). Association between portosystemic shunts and increased complications and mortality in patients with cirrhosis. *Gastroenterology*, *154*(6), 1694-1705.

[8] Porcheron, J., & Balique, J. G. (1995, October). Physiopathology and surgical treatment of hepatic encephalopathy after porto-caval anastomosis. In *Annales de Gastroenterologie et D'hepatologie* (Vol. 31, No. 5, pp. 287-294).

[9] Ridola, L., Cardinale, V., & Riggio, O. (2018). The burden of minimal hepatic encephalopathy: from diagnosis to therapeutic strategies. *Annals of Gastroenterology*, *31*(2), 151.

[10] Nardelli, S., Gioia, S., Faccioli, J., Riggio, O., & Ridola, L. (2019). Sarcopenia and cognitive impairment in liver cirrhosis: A viewpoint on the clinical impact of minimal hepatic encephalopathy. *World Journal of Gastroenterology*, *25*(35), 5257.

[11] Bustamante, J., Rimola, A., Ventura, P. J., Navasa, M., Cirera, I., Reggiardo, V., & Rodés, J. (1999). Prognostic significance of hepatic encephalopathy in patients with cirrhosis. *Journal of hepatology*, *30*(5), 890-895.

[12] Montagnese, S., Russo, F. P., Amodio, P., Burra, P., Gasbarrini, A., Loguercio, C., ... & Scarpignato, C. (2019). Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver

ISSN: 2583-4053

Volume-3 Issue-3 || June 2024 || PP. 170-180

https://doi.org/10.55544/jrasb.3.3.27

(AISF). *Digestive and liver disease*, *51*(2), 190-205.

[13] Patidar, K. R., & Bajaj, J. S. (2015). Covert and overt hepatic encephalopathy: diagnosis and management. *Clinical Gastroenterology and Hepatology*, *13*(12), 2048-2061.

[14] Vilstrup, H., Amodio, P., Bajaj, J., Cordoba, J., Ferenci, P., Mullen, K. D., ... & Wong, P. (2014). Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. *Hepatology*, *60*(2), 715-735.

[15] Gerber, T., & Schomerus, H. (2000). Hepatic encephalopathy in liver cirrhosis: pathogenesis, diagnosis and management. *Drugs*, *60*, 1353-1370.

[16] Poordad, F. F. (2007). The burden of hepatic encephalopathy. *Alimentary pharmacology & therapeutics*, *25*, 3-9.

[17] Bustamante, J., Rimola, A., Ventura, P. J., Navasa, M., Cirera, I., Reggiardo, V., & Rodés, J. (1999). Prognostic significance of hepatic encephalopathy in patients with cirrhosis. *Journal of hepatology*, *30*(5), 890-895.

[18] Wong, R. J., Gish, R. G., & Ahmed, A. (2014). Hepatic encephalopathy is associated with significantly increased mortality among patients awaiting liver transplantation. *Liver Transplantation*, *20*(12), 1454-1461.

[19] Tapper, E. B., Jiang, Z. G., & Patwardhan, V. R. (2015, May). Refining the ammonia hypothesis: a physiology-driven approach to the treatment of hepatic encephalopathy. In *Mayo Clinic Proceedings* (Vol. 90, No. 5, pp. 646-658). Elsevier.

[20] Romero-Gómez, M., Jover, M., Del Campo, J. A., Royo, J. L., Hoyas, E., Galán, J. J., ... & Ruiz, A. (2010). Variations in the promoter region of the glutaminase gene and the development of hepatic encephalopathy in patients with cirrhosis: a cohort study. *Annals of internal medicine*, *153*(5), 281-288.

[21] Bajaj, J. S., Heuman, D. M., Hylemon, P. B., Sanyal, A. J., White, M. B., Monteith, P., ... & Gillevet, P. M. (2014). Altered profile of human gut microbiome is associated with cirrhosis and its complications. *Journal of hepatology*, *60*(5), 940-947.

[22] Shawcross, D., & Jalan, R. (2005). The pathophysiologic basis of hepatic encephalopathy: central role for ammonia and inflammation. *Cellular and Molecular Life Sciences CMLS*, *62*, 2295-2304.

[23] Liu, Q., Duan, Z. P., Ha, D. K., Bengmark, S., Kurtovic, J., & Riordan, S. M. (2004). Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. *Hepatology*, *39*(5), 1441-1449.

[24] Dam, G., Vilstrup, H., Watson, H., & Jepsen, P. (2016). Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites. *Hepatology*, *64*(4), 1265-1272.

[25] Goldbecker, A., Weissenborn, K., Shahrezaei, G. H., Afshar, K., Rümke, S., Barg-Hock, H., ... & Tryc, A. B. (2013). Comparison of the most favoured methods for the diagnosis of hepatic encephalopathy in liver transplantation candidates. *Gut*, *62*(10), 1497-1504.

[26] Hawkins, R. A., Jessy, J., Mans, A. M., Chedid, A., & DeJoseph, M. R. (1994). Neomycin reduces the intestinal production of ammonia from glutamine. *Hepatic Encephalopathy, Hyperammonemia, and Ammonia Toxicity*, 125-134.

[27] Sharma, K., Akre, S., Chakole, S., & Wanjari, M. B. (2022). Hepatic Encephalopathy and Treatment Modalities: A Review Article. *Cureus*, *14*(8), e28016. https://doi.org/10.7759/cureus.28016

[28] Tapper, E. B., Parikh, N. D., Sengupta, N., Mellinger, J., Ratz, D., Lok, A. S. F., & Su, G. L. (2018). A risk score to predict the development of hepatic encephalopathy in a population-based cohort of patients with cirrhosis. *Hepatology*, *68*(4), 1498-1507.

[29] Orman, E. S., Roberts, A., Ghabril, M., Nephew, L., Desai, A. P., Patidar, K., & Chalasani, N. (2019). Trends in characteristics, mortality, and other outcomes of patients with newly diagnosed cirrhosis. *JAMA network open*, *2*(6), e196412-e196412.

[30] Potnis, A., VanMeter, S., & Stange, J. (2021). Prevalence of hepatic encephalopathy from a commercial medical claims database in the United States. *International Journal of Hepatology*, *2021*(1), 8542179.

[31] American Association for the Study of Liver Diseases. (2014). Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. *Journal of hepatology*, *61*(3), 642-59.

[32] Amodio, P. (2015). Hepatic encephalopathy: historical remarks. *Journal of Clinical and Experimental Hepatology*, *5*, S4-S6.

[33] Parsons-Smith, B. G., Summerskill, W. H. J., Dawson, A. M., & Sherlock, S. (1957). The electroencephalograph in liver disease. *The Lancet*, *270*(7001), 867-871.

[34] Rikkers, L., Jenko, P., Rudman, D., & Freides, D. (1978). Subclinical hepatic encephalopathy: detection, prevalence, and relationship to

ISSN: 2583-4053

Volume-3 Issue-3 || June 2024 || PP. 170-180

https://doi.org/10.55544/jrasb.3.3.27

nitrogen metabolism. *Gastroenterology*, *75*(3), 462-469.

[35] Ferenci, P., Lockwood, A., Mullen, K., Tarter, R., Weissenborn, K., & Blei, A. T. (2002). Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. *Hepatology*, *35*(3), 716-721.

[36] Córdoba, J. (2011). New assessment of hepatic encephalopathy. *Journal of hepatology*, *54*(5), 1030-1040.

[37] Bajaj, J. S., Cordoba, J., Mullen, K. D., Amodio, P., Shawcross, D. L., Butterworth, R. F., & Morgan, M. Y. (2011). the design of clinical trials in hepatic encephalopathy–an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. *Alimentary pharmacology & therapeutics*, *33*(7), 739-747.

[38] Hassanein, T. I., Hilsabeck, R. C., & Perry, W. (2008). Introduction to the hepatic encephalopathy scoring algorithm (HESA). *Digestive diseases and sciences*, *53*, 529-538.

[39] Hassanein, T., Blei, A. T., Perry, W., Hilsabeck, R., Stange, J., Larsen, F. S., ... & Fontana, R. (2009). Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy. *Official journal of the American College of Gastroenterology| ACG*, *104*(6), 1392-1400.

[40] Ortiz, M., Cordoba, J., Doval, E., Jacas, C., Pujadas, F., Esteban, R., & Guardia, J. (2007). Development of a clinical hepatic encephalopathy staging scale. *Alimentary pharmacology & therapeutics*, *26*(6), 859-867.

[41] Bajaj, J. S., Wade, J. B., & Sanyal, A. J. (2009). Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy. *Hepatology*, *50*(6), 2014-2021.

[42] Montagnese, S., Balistreri, E., Schiff, S., De Rui, M., Angeli, P., Zanus, G., ... & Amodio, P. (2014). Covert hepatic encephalopathy: agreement and predictive validity of different indices. *World journal of gastroenterology: WJG*, *20*(42), 15756.

[43] Thomsen, K. L., Macnaughtan, J., Tritto, G., Mookerjee, R. P., & Jalan, R. (2016). Clinical and pathophysiological characteristics of cirrhotic patients with grade 1 and minimal hepatic encephalopathy. *PloS one*, *11*(1), e0146076.

[44] Montagnese, S., De Rui, M., Angeli, P., & Amodio, P. (2017). Neuropsychiatric performance in patients with cirrhosis: Who is "normal"?. *Journal of hepatology*, *66*(4), 825–835. https://doi.org/10.1016/j.jhep.2016.11.021

[45] American Association for the Study of Liver Diseases. (2014). Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. *Journal of hepatology*, *61*(3), 642-59.

[46] Guerit, J. M., Amantini, A., Fischer, C., Kaplan, P. W., Mecarelli, O., Schnitzler, A., ... & members of the ISHEN commission on Neurophysiological Investigations. (2009). Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines. *Liver International*, *29*(6), 789-796.

[47] Randolph, C., Hilsabeck, R., Kato, A., Kharbanda, P., Li, Y. Y., Mapelli, D., ... & Weissenborn, K. (2009). Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. *Liver international*, *29*(5), 629-635.

[48] Prakash, R. K., Brown, T. A., & Mullen, K. D. (2011). Minimal hepatic encephalopathy and driving: is the genie out of the bottle?. *Official journal of the American College of Gastroenterology| ACG*, *106*(8), 1415-1416.

[49] Lockwood, A. H. (2004). Blood ammonia levels and hepatic encephalopathy. *Metabolic brain disease*, *19*, 345-349.

[50] Sharma, K., Akre, S., Chakole, S., & Wanjari, M. B. (2022). Hepatic Encephalopathy and Treatment Modalities: A Review Article. *Cureus*, *14*(8), e28016. https://doi.org/10.7759/cureus.28016

[51] Ferenci, P., Herneth, A., & Steindl, P. (1996). Newer approaches to therapy of hepatic encephalopathy. In *Seminars in liver disease* (Vol. 16, No. 03, pp. 329-338). © 1996 by Thieme Medical Publishers, Inc..

[52] Conn, H. O., Leevy, C. M., Vlahcevic, Z. R., Rodgers, J. B., Maddrey, W. C., Seeff, L., & Levy, L. L. (1977). Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy: a double blind controlled trial. *Gastroenterology*, *72*(4), 573-583.

[53] Sharma, P., & Sarin, S. K. (2012). Disaccharides in the treatment of hepatic encephalopathy. *Hepatic Encephalopathy*, 141-158.

[54] Miglio, F., Valpiani, D., Ricca Rossellini, S., Ferrieri, A., & Canova, N. (1997). Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial. *Current medical research and opinion*, *13*(10), 593-601.

ISSN: 2583-4053

Volume-3 Issue-3 || June 2024 || PP. 170-180

https://doi.org/10.55544/jrasb.3.3.27

[55] Strauss, E., Tramote, R., Silva, E. P., Caly, W. R., Honain, N. Z., Maffei, R. A., & de Sá, M. F. (1992). Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. *Hepato-gastroenterology*, *39*(6), 542-545.

[56] Korean Association for the Study of the Liver (KASL. (2020). KASL clinical practice guidelines for liver cirrhosis: varices, hepatic encephalopathy, and related complications. *Clinical and molecular hepatology*, *26*(2), 83.

[57] Martin, P., DiMartini, A., Feng, S., Brown Jr, R., & Fallon, M. (2014). Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. *Hepatology*, *59*(3), 1144-1165.

[58] Ferenci P. (2017). Hepatic encephalopathy. *Gastroenterology report*, *5*(2), 138–147. https://doi.org/10.1093/gastro/gox013

[59] Green, E. W., & Mitra, A. (2022). Diagnosis and management of hepatic encephalopathy: A summary for patients. *Clinical liver disease*, *20*(3), 90–92. https://doi.org/10.1002/cld.1236

[60] Ridola, L., Faccioli, J., Nardelli, S., Gioia, S., & Riggio, O. (2020). Hepatic Encephalopathy: Diagnosis and Management. *Journal of translational internal medicine*, *8*(4), 210–219. https://doi.org/10.2478/jtim-2020-0034

[61] Riggio, O., Ridola, L., & Pasquale, C. (2010). Hepatic encephalopathy therapy: An overview. *World journal of gastrointestinal pharmacology and therapeutics*, *1*(2), 54–63. https://doi.org/10.4292/wjgpt.v1.i2.54

[62] Hoilat, G. J., Suhail, F. K., Adhami, T., & John, S. (2022). Evidence-based approach to management of hepatic encephalopathy in adults. *World journal of hepatology*, *14*(4), 670–681. https://doi.org/10.4254/wjh.v14.i4.670

[63] Elwir, S., & Rahimi, R. S. (2017). Hepatic Encephalopathy: An Update on the Pathophysiology and Therapeutic Options. *Journal of clinical and translational hepatology*, *5*(2), 142–151. https://doi.org/10.14218/JCTH.2016.00069

[64] Poh, Z., & Chang, P. E. (2012). A current review of the diagnostic and treatment strategies of hepatic encephalopathy. *International journal of hepatology*, *2012*, 480309. https://doi.org/10.1155/2012/480309

[65] Chela, H. K., Basra, N., & Naqvi, S. H. (2019). Hepatic Encephalopathy in the Hospitalized Patient: A Review for Hospitalists. *Missouri medicine*, *116*(4), 308–312.